Search

Your search keyword '"Castaman G"' showing total 117 results

Search Constraints

Start Over You searched for: Author "Castaman G" Remove constraint Author: "Castaman G" Publication Year Range Last 3 years Remove constraint Publication Year Range: Last 3 years
117 results on '"Castaman G"'

Search Results

1. Determinants of bleeding before and during immune tolerance in 222 boys with severe hemophilia A and inhibitors >5 BU

2. The value‐based healthcare approach to haemophilia: Development of outcome measures for the evaluation of care of people with haemophilia

3. PCR191 Assessing Quality of Care in Haemophilia Using a Value-Based Healthcare Approach

11. PB0642 Determinants of the Bleeding Phenotype in Persons with Non-Severe Hemophilia

12. Translational readthrough at F8 nonsense variants in factor VIII B domain contributes to residual expression and lowers inhibitor association

13. Determinants of bleeding before and during immune tolerance in 222 boys with severe hemophilia A and inhibitors >5 BU

15. Pain relief with Eptacog beta in haemophilia patients with inhibitors

16. Adults with severe or moderately severe haemophilia B receiving etranacogene dezaparvovec in the HOPE-B phase 3 trial experience a stable increase in mean Factor IX activity levels and durable haemostatic protection after 24 months’ follow-up

17. Durability of bleeding protection and Factor IX activity in individuals with and without adeno-associated virus serotype 5 neutralising antibodies (Titres <1:700) in the phase 3 HOPE-B trial of etranacogene dezaparvovec gene therapy for haemophilia B

20. LARGE DELETIONS IN THE F8 GENE PREDICT IMMUNE TOLERANCE INDUCTION FAILURE IN PEOPLE WITH SEVERE HEMOPHILIA A

22. The bleeding phenotype in people with nonsevere hemophilia

24. Real-world clinical and psychosocial outcomes among people with mild or moderate haemophilia A treated on-demand in the Italian CHESS II cohort: a real-world data analysis

29. Phase 3 Trial of Concizumab in Hemophilia with Inhibitors.

30. Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B.

31. Translational readthrough at F8 nonsense variants in factor VIII B domain contributes to residual expression and lowers inhibitor association

32. Next-generation strategies to improve safety and efficacy of adeno-associated virus-based gene therapy for hemophilia: lessons from clinical trials in other gene therapies.

33. Intracranial hemorrhage before start of prophylaxis in children with hemophilia: incidence, timing, and potential for prevention.

34. Liver-related aspects of valoctocogene roxaparvovec gene therapy for hemophilia A: expert guidance for clinical practice.

35. The Unmet Needs of Lysosomal Storage Disorders from Early Diagnosis to Caregiving Pathways: An Italian Perspective.

36. Gene therapy for people with hemophilia B: a proposed care delivery model in Italy.

37. Prediction of the chance of successful immune tolerance induction in persons with severe hemophilia A and inhibitors: a clinical prediction model.

38. Keep it positive: loss of positive charge induced by R1205H von Willebrand factor change accelerates von Willebrand factor clearance through enhanced binding to macrophage clearance receptors LRP1 and SR-A1.

40. Invasive procedures and surgery following etranacogene dezaparvovec gene therapy in people with hemophilia B.

41. Pharmacokinetic model-based assessment of factor IX prophylaxis treatment regimens in severe hemophilia B.

42. Pharmacokinetics of Efmoroctocog alfa by Two-Compartment Model Highlights Hemophilia A Patients with Biphasic Decay, Long Mean Residence Time, and Beta Half-Life.

43. Outcome measures in hemophilia: current and future perspectives.

44. Real-world experience of rIX-FP prophylaxis at dosing intervals of 14 days or more in adult patients with haemophilia B in Italy - Results from IDEAL Part B.

45. Exposure-Response Relationship between VWF/FVIII Activity and Spontaneous Bleeding Events Following Recombinant VWF Prophylaxis in Severe VWD.

46. Concizumab prophylaxis in persons with hemophilia A or B with inhibitors: patient-reported outcome results from the phase 3 explorer7 study.

47. Gene Therapy for Hemophilia B: Achievements, Open Issues, and Perspectives.

48. Physical Activity, Bleedings and Quality of Life in Subjects with Haemophilia A without Inhibitors-A Multicenter, Observational Italian Study with a Wearable Device.

49. Is pharmacological thromboprophylaxis necessary in persons with haemophilia undergoing major orthopaedic surgery?

50. Pattern of use and clinical outcomes with rIX-FP in pediatric/adolescent patients with haemophilia B in Italy: Results from IDEAL real-world study.

Catalog

Books, media, physical & digital resources